CRP and prostate carcinoma: Regarding the chronic inflammation indices of cancer patients and survivors, a meta-analysis of C-reactive protein showed that the intervention reduced this [(MD = −0.97, CI = (−1.88)–(−0.06), Z = 2.09, I2 = 69%, and p = 0.01; Figure 8], whereas a subgroup analysis revealed that this occurs only in patients and survivors with breast cancer but not in those with prostate cancer (p = 0.02 and I2 = 82.2%; Figure 8).